PA-EXONE-CO.
The ExOne Company (Nasdaq: XONE), the global leader in industrial sand and metal 3D printers using binder jetting technology, today announced that global manufacturing innovation leader Siemens is the first of several customers to place an advance purchase for the InnoventPro 3L metal 3D printer.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211109005404/en/
The InnoventPro is the world’s most advanced entry-level model for metal binder jetting — designed to take the easy-to-use features of the popular Innovent+ with patented Triple ACT advanced compaction technology and offer them with a bigger build area and the best speed and cutting-edge technology features of ExOne’s production-ready printers, such as the X1 25Pro® and X1 160Pro™.
The InnoventPro is slated to be on display for the first time in ExOne’s booth in Hall 12.0, Booth D69 at Formnext 2021 from Nov. 16-19 in Frankfurt, Germany. The machine is available for early-access machine customers in the first half of 2022, with broad availability to follow.
The InnoventPro features Siemens controls, which integrate with the printer drives, motors, sensors, as well as Siemens MindSphere IoT operating system, which powers ExOne’s Scout machine monitoring and analysis app.
Siemens will use the InnoventPro at its Charlotte Advanced Technology Collaboration Hub (CATCH) located in Charlotte, North Carolina to develop materials and processes before taking them to scale on the X1 160Pro.
“We’re very excited to feature the InnoventPro in our Technology Collaboration Hub, and we look forward to demonstrating how to integrate advanced additive manufacturing systems such as the InnoventPro into our end-to-end Digital Thread,” said Tim Bell, Head of Additive Manufacturing, Siemens Industry, Inc. The CATCH facility will leverage Siemens advanced hardware automation and software tools to continue the industrialization of additive manufacturing.
“ExOne is proud to continue offering Siemens technologies in our production-ready metal binder jetting systems, and we’re delighted that Siemens has purchased our new InnoventPro for its own manufacturing use,” said John Hartner, ExOne’s CEO. “Siemens technology continues to deliver important integration value to our production customers, and we’re confident our printer will deliver important manufacturing value to their operations as well.”
InnoventPro Feature Highlights
The affordable new InnoventPro is an all-new package built from the ground up that gives binder jetting customers the most advanced entry-level system on the market in a 3-liter build area of 125 x 220 x 100 mm. Features include:
- Triple ACT advanced compaction technology for precision dispensing, spreading, and compacting of ultra-fine MIM powders, delivering the industry-leading density, accuracy and repeatability that was proven on the Innovent+
- Now packaged with the same faster, smarter, recirculating printhead modules that come standard on ExOne production printers, enabling easy scalability to larger models
- The new printhead will be capable of speeds topping 700 cc/hour on the InnoventPro and printing a new class of patented NanoFuse™ binders embedded with nanoparticles to improve part quality and simplify sintering
- An innovative new comprehensive powder containment system, featuring the ergonomic X1 Powder Grip™ loading system, delivers ease-of-use and improved cleanliness
- Siemens MindSphere powers ExOne’s Scout machine monitoring and analysis app, part of ExOne’s strategy to surround its printers with a complete digital workflow. Scout is available today in the Apple App Store and on Google Play for use with ExOne production sand and metal 3D printers
The InnoventPro was designed by ExOne’s experienced binder jet engineering team based in Pittsburgh, Pennsylvania, and Gersthofen, Germany, with final manufacturing and assembly done in the United States.
Learn more about the InnoventPro at exone.com/innoventpro .
About ExOne
ExOne (Nasdaq: XONE) is the pioneer and global leader in binder jet 3D printing technology. Since 1995, we’ve been on a mission to deliver powerful 3D printers that solve the toughest problems and enable world-changing innovations. Our 3D printing systems quickly transform powder materials — including metals, ceramics, composites and sand — into precision parts, metalcasting molds and cores, and innovative tooling solutions. Industrial customers use our technology to save time and money, reduce waste, improve their manufacturing flexibility, and deliver designs and products that were once impossible. As home to the world’s leading team of binder jetting experts, ExOne also provides specialized 3D printing services, including on-demand production of mission-critical parts, as well as engineering and design consulting. Learn more about ExOne at www.exone.com or on Twitter at @ExOneCo. We invite you to join with us to #MakeMetalGreen™.
About Siemens Digital Industries
Siemens Digital Industries (DI) is an innovation leader in automation and digitalization. Closely collaborating with partners and customers, DI drives the digital transformation in the process and discrete industries. With its Digital Enterprise portfolio, DI provides companies of all sizes with an end-to-end set of products, solutions and services to integrate and digitalize the entire value chain. Optimized for the specific needs of each industry, DI’s unique portfolio supports customers to achieve greater productivity and flexibility. DI is constantly adding innovations to its portfolio to integrate cutting-edge future technologies. Siemens Digital Industries has its global headquarters in Nuremberg, Germany, and has around 75,000 employees internationally.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211109005404/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Crown Bioscience Expands US Presence with New Model Development Center in Kannapolis, North Carolina17.9.2025 14:30:00 CEST | Press release
Crown Bioscience, a global contract research organization (CRO) headquartered in the United States and part of JSR Life Sciences and Japan-based JSR Corporation, today announced the opening of a state-of-the-art model development center in Kannapolis, North Carolina. This strategic investment expands the company’s operations and enhances its ability to deliver advanced preclinical oncology models, including patient-derived xenografts (PDX), PDX warm models, PDX-derived organoids (PDXO), and patient-derived organoids (PDO), to meet the evolving needs of pharmaceutical and biotechnology companies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917864004/en/ Crown Bioscience celebrate the official ribbon-cutting ceremony for the company’s new Kannapolis, North Carolina facility, marking an expansion of US oncology model development and preclinical CRO services. The new facility strengthens Crown Bioscience’s US-based capabil
SBC Medical Accelerates Multi-Brand Strategy with Hybrid Dermatology Model “Hada no Aozora Clinic” Establishment17.9.2025 14:00:00 CEST | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced the launch of a new brand, “Hada no Aozora Clinic”, scheduled to open in Tokyo on October 1, 2025. This clinic will adopt a hybrid dermatology model that integrates insurance-covered general dermatology and private-pay aesthetic treatments, advancing SBC’s multi-brand strategy in the rapidly expanding aesthetic medicine market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917897380/en/ SBC Medical Accelerates Multi-Brand Strategy with Hybrid Dermatology Model “Hada no Aozora Clinic” Establishment As life expectancy continues to rise and demographic aging accelerates, more people are seeking treatments that help them maintain both well-being and a youthful appearance over a longer lifespan. Within this environment, aesth
Rubedo Life Sciences Announces U.S. FDA Clearance of IND for Selective GPX4 Modulating Lead Drug Candidate RLS-1496 for Actinic Keratosis, Expands Clinical Advisory Board17.9.2025 14:00:00 CEST | Press release
IND clearance marks second study accepted for RLS-1496, a first-in-class disease-modifying selective GPX4 modulator targeting pathological senescent cells that drive inflammaging and chronic degenerative diseases and conditions associated with the biological aging process through ferroptosis Results from first RLS-1496 study in patients with psoriasis, atopic dermatitis, and skin aging are expected in Q4 2025; the actinic keratosis Phase 1b/2a study will begin in Q4 2025 Rubedo Clinical Advisory Board expands to include globally renowned dermatologist and immunologist Emma Guttman-Yassky, MD, PhD., Waldman Professor of Dermatology and Immunology and Health System Chair of the Kimberly and Eric J. Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, today announced that the U.S
New Study Finds That Using Masimo Technologies to Continuously Monitor General Floor Patients Reduces Costs17.9.2025 14:00:00 CEST | Press release
Universal Surveillance Monitoring with Masimo SET® Pulse Oximetry and Patient SafetyNet™ – Repeatedly Shown to Improve Patient Outcomes and Save Lives – Also Projected to Yield Significant Cost Savings Masimo (NASDAQ: MASI) today announced the findings of a study published in the Journal of Patient Safety in which Dr. George Blike and colleagues at Dartmouth-Hitchcock Medical Center in New Hampshire demonstrated that use of Masimo technologies to continuously monitor general floor patients can yield significant cost savings.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917266545/en/ Continuous Patient Monitoring with Masimo SET® Pulse Oximetry and Patient SafetyNet™ In prior studies, the clinical outcome benefits of continuously monitoring patients using Masimo SET® and Patient SafetyNet™ have been shown to include lower mortality, improved resuscitative outcomes, and fewer rapid response team activations and transfers
Merck to Present New Data Highlighting Durable Effects of MAVENCLAD® in Relapsing Multiple Sclerosis (RMS) at ECTRIMS 202517.9.2025 14:00:00 CEST | Press release
Four-year data show nearly 9 in 10 RMS patients remained free from progression independent of relapse activity (PIRA)Results highlight the potential of MAVENCLAD to reduce neurodegeneration and neuroinflammation beyond established clinical efficacy outcomes in RMSEvidence suggests that MAVENCLAD effectiveness could be driven by peripheral and central effects without requiring continuous immunosuppression Not intended for UK-, US- or Canada-based media Merck, a leading science and technology company, today announced the presentation of over 30 abstracts from its multiple sclerosis (MS) portfolio. New four-year data from two large Phase 4 studies highlight the long-term efficacy, favorable disability outcomes and durable impact of MAVENCLAD® (cladribine tablets) in people living with relapsing multiple sclerosis (RMS). These findings are to be presented at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), being held September 24-26 in
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom